Articles from MedImpact Healthcare Systems, Inc.

MedImpact Holdings’ strategic investment in health tech startup Bayvrio is accelerating the rollout of Bayvrio’s advanced technology platform and first-of-its-kind marketplace, the two companies announced today. Due to this investment, these solutions are now available to health systems, pharmacy benefit managers, and third-party administrators seeking greater flexibility and control over how they manage benefits, care, and costs.

MedImpact Healthcare Systems, the nation’s largest independent provider of health solutions, technology, and pharmacy benefit management services, announced that it is expanding access to two biosimilar alternatives to Stelara (ustekinumab), Selarsdi (ustekinumab-aekn) and Yesintek (ustekinumab-kfce). Consistent with its mission of delivering affordability without compromising access, MedImpact’s approach to biosimilars is pharmacy- and manufacturer-neutral.

MedImpact Healthcare Systems, Inc., the nation’s largest independent provider of health solutions, technology, and pharmacy benefit services, announced today that in the first half of 2024, its innovative MedImpactSaveTM program saved consumers on average $18.88 per prescription, while reducing drug spend for healthcare payers.

MedImpact, the largest independent pharmacy benefit manager and health solutions company, today unveiled MedEmpower FuelTM, a personalized, integrated, whole health approach to nutrition, weight loss, and chronic condition management. Incorporating a consumer app, coaching, and advanced clinical support, MedEmpower Fuel offers a tiered approach to engaging members with the greatest health challenges and risks to improve care and control costs.

MedImpact Healthcare Systems, Inc., the nation’s largest independent provider of health solutions, technology, and pharmacy benefit services, today announced that it is expanding access to Humira biosimilars, Simlandi and adalimumab-adaz, for new patients requiring medication for inflammatory conditions such as Crohn’s disease or rheumatoid arthritis. Patients already taking Humira through their pharmacy benefit can continue to do so, and new patients who have taken one of the two biosimilars but did not see the desired results may switch to Humira.

MedImpact Healthcare Systems, Inc., the nation’s largest independent provider of health solutions, technology, and pharmacy benefit management services, announced today that it has successfully completed the integration of Elixir Solutions. In addition to increasing MedImpact’s scale and portfolio of solutions, the acquisition was critical to safeguarding more than 1,000 jobs previously at risk due to Rite Aid's bankruptcy and ensuring the continuity in prescription services for millions of Elixir members.

MedImpact Healthcare Systems, Inc., the nation’s largest independent health solutions, technology, and pharmacy benefit management provider, announced today that it has completed the acquisition of Elixir Solutions. This is the latest addition and part of MedImpact’s ongoing reinvestment strategy. The acquisition expands the company’s portfolio of clinical, technology, health risk management, and consumer empowerment capabilities.